Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study

Table 1 Subgroup analyses of 3-year disease-free survival

Subgroups	Events/number	3-year DFS, % (95% CI)	P-value*
pCR
No	6/14	63.5 (33.1, 83.0)	0.018
Yes	0/13	100.0 (100.0, 100.0)
Postoperative pathological node status
pN +	5/8	50.0 (15.2, 77.5)	0.003
pN0	1/19	94.4 (66.6, 99.2)
PD-L1 CPS
< 1	6/20	74.3 (48.7, 88.4)	0.242
≥ 1	0/6	100.0 (100.0, 100.0)
Baseline CRM status assessed by MRI
Positive	6/18	69.5 (41.3, 86.1)	0.036
Negative	0/9	100.0 (100.0, 100.0)
Baseline EMVI status
Positive	6/11	54.5 (22.9, 78.0)	0.002
Negative	0/16	100.0 (100.0, 100.0)

^*P-value was nominal, as determined by log-rank test. CI, confidence interval; CPS, combined positive score; CRM, circumferential resection margin; DFS, disease-free survival; EMVI, extramural venous invasion, MRI, magnetic resonance imaging; pCR, pathological complete response; PD-L1, programmed cell death-ligand 1

ISSN: 1741-7015